I. Executive Summary Background The 5 years since the publication of the first International
Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed …

Summary European Respiratory Society guidelines for the management of adult
bronchiectasis highlight the paucity of treatment options available for patients with this …

CFTR modulators have dramatically changed the clinical course of CF in those fortunate
enough to receive them. Inevitably, randomised controlled trials during the development of …

Background The cystic fibrosis transmembrane conductance regulator (CFTR) potentiator,
ivacaftor, was first approved for people with CF and the G551D CFTR mutation. This study …

Background Cystic fibrosis (CF) lung transplant (LT) recipients may warrant treatment with
elexacaftor/tezacaftor/ivacaftor (ETI) to improve extrapulmonary manifestations of CF. Our …

This is the final of four papers updating standards for the care of people with CF. That this
paper “Planning a longer life” was considered necessary, highlights how much CF care has …

Educational aims To recognise the clinical and radiological presentation of the spectrum of
diseases associated with bronchiectasis. To understand variation in the aetiology …

Cystic fibrosis (CF) is an autosomal recessive genetic disease caused by variants in the
gene encoding the cystic fibrosis transmembrane conduction regulator (CFTR) protein. Loss …

Highly effective modulator therapies (HEMTs) have revolutionised the management
approach of most patients living with cystic fibrosis (CF) who have access to these therapies …

Objectives Published cost estimates for cystic fibrosis (CF) are based on older data and do
not reflect increased use of specialty drugs in recent years. We assessed recent trends in …